Oslo, Norway, 28 April 2026 - Oncoinvent ASA (ONCIN), will be holding its Annual
General Meeting virtual on 20 May 2026 at 10:00 hours (CEST).

The notice and agenda of the annual general meeting is attached hereto,
including further information on advance voting, power of attorney and physical
participation. The notice will be sent to all registered shareholders, and the
notice, the compensation report, the nomination committees recommendations and
other documents referred to therein are made available on the Company's website:
https://www.oncoinvent.com/investors/general-meetings/.

Oncoinvent ASA - Notice to AGM
2026.pdf (https://mb.cision.com/Public/15728/4341307/91b5ce77dcea1d84.pdf)

All shareholders are encouraged to exercise their shareholder rights, either
through advance electronically voting through VPS Investor Services, by using
the enclosed proxy form to provide proxy to the Chairman Gillies O'Bryan-Tear
(or the person he appoints), or to attend the general meeting virtually.

Registration, advance vote or proxy for the Annual General Meeting can be
registered through the company's
website (https://www.oncoinvent.com/investors/general-meetings/) or VPS Investor
Service (https://investor.vps.no/garm/auth/login) within 18 May 2026, 23:59
hours (CEST). Virtual participants also need to be logged in to the meeting
before 10:00 hours (CEST) 20 May 2026. All shareholders will receive a reference
number and a pin code required for registration through the company's website.
Reference number and pin code will be received either by VPS Investor Service or
by post depending on if the shareholder is registered as electronical user. We
encourage all shareholders to register as electronical users in VPS.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: [email protected] ([email protected])

This information is subject to the disclosure requirements pursuant to Euronext
Oslo Rule Book II for companies listed on Oslo Børs and Section 5-12 of the
Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation
therapy that leverages the unique anatomy of the abdominal cavity to destroy
residual micrometastases using a single, highly localized dose of alpha
radiation. The initial clinical focus is treatment of ovarian and colorectal
cancer patients after surgical removal of the primary tumor and visible
metastases in the peritoneum, the thin membrane lining the abdominal cavity and
covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the
peritoneal cavity, keeping patients disease-free for longer than the current
standard of care and thereby also impacting overall survival. It is broadly
applicable to any cancer that spreads to the peritoneum, e.g. ovarian,
colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity,
excellent safety profile, and seamless integration into existing surgical
workflows. Oncoinvent's product is easy to use, avoids systemic delivery and
significant toxicity. It is also differentiated in being simple to manufacture,
scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers,
are highly promising, showing an excellent safety profile and meaningful signals
of efficacy. Interim data from an ongoing, randomized, controlled phase 2
ovarian cancer trial is expected in 2026. With cost-effective manufacturing,
blockbuster potential, active pharma partnership momentum, plus strong
endorsements from leading experts, Oncoinvent is built for scale and commercial
success, and is set to become the new standard for post-surgical cancer care.
The Company was founded by the originators of Algeta and Xofigo (acquired by
Bayer).